UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,497 Shares of ANI Pharmaceuticals, Inc. $ANIP

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 29.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 42,279 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,497 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ANI Pharmaceuticals were worth $3,500,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp raised its stake in ANI Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG boosted its stake in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after acquiring an additional 91,153 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after acquiring an additional 43,523 shares during the last quarter. Finally, Tang Capital Management LLC increased its holdings in shares of ANI Pharmaceuticals by 51.6% during the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after acquiring an additional 163,937 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen Carey sold 2,850 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer owned 171,843 shares of the company’s stock, valued at approximately $12,510,170.40. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,425 shares of company stock worth $1,687,370 over the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $104.00 price target for the company. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group dropped their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.57.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $71.46 on Friday. The firm has a market cap of $1.64 billion, a P/E ratio of 15.40 and a beta of 0.45. The business’s 50 day moving average is $77.58 and its 200-day moving average is $78.25. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 1-year low of $69.96 and a 1-year high of $99.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the company posted $1.80 EPS. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.